Paclitax 260mg Injection

• Breast cancer
• Pancreatic cancer
• Non-small cell lung cancer​
  

Undesired symptoms or responses vary from person to person as the human body reacts differently to the Paclitax 260mg Injection  , but they typically resolve naturally within a few days as the body adjusts to the medicine, requiring no medical attention. In case these symptoms don't go away and you face severe side effects, then immediately consult your doctor or medical team.

Some of the common side effects of the are:

• Nausea
• Vomiting
• Weakness
• Low blood platelets
• Rash
• Upper respiratory tract infection
• Urinary tract infection
• Bleeding
• Anemia (low number of red blood cells)
• Flushing (sense of warmth in the face, ears, neck and trunk)
• Hair loss
• Decreased blood pressure
• Peripheral neuropathy (tingling and numbness of feet and hand)
• Diarrhea
• Decreased white blood cell count (neutrophils

• Paclitax 260mg Injection is a prescription-based medicine that is injected intravenously by a doctor or an experienced nurse under strict medical supervision. It is not intended for self-administration.
• The doctor will determine the appropriate dosage and duration of treatment based on the type and stage of cancer, as well as the patient's health condition. It can be used alone or in combination with other medicines during the treatment.
  

• Awasthi, N., Scire, E., Monahan, S., Grojean, M., Zhang, E., Schwarz, M. A., & Schwarz, R. E. (2016). Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models. Oncotarget, 7(30), 46988.
• Xiao, Z., Wang, C., Zhou, M., Hu, S., Jiang, Y., Huang, X., ... & Li, X. (2019). Clinical efficacy and safety of Aidi injection plus paclitaxel-based chemotherapy for advanced non-small cell lung cancer: a meta-analysis of 31 randomized controlled trials following the PRISMA guidelines. Journal of Ethnopharmacology, 228, 110-122.
• Wang, Z., Li, W., Jiang, Y., Ma, T., Li, M., Wu, S., ... & Lu, J. (2025). A sphingolipid-derived paclitaxel nanovesicle enhances efficacy of combination therapies in triple-negative breast cancer and pancreatic cancer. Nature cancer, 6(10), 1734-1753.
• Perez-Soler, R., Kemp, B., Wu, Q. P., Mao, L., Gomez, J., Zeleniuch-Jacquotte, A., ... & Ling, Y. H. (2000). Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumorsheterotransplanted in nude mice. Clinical cancer research, 6(12), 4932-4938.
• Soma, D., Kitayama, J., Ishigami, H., Kaisaki, S., & Nagawa, H. (2009). Different tissue distribution of paclitaxel with intravenous and intraperitoneal administration. Journal of Surgical Research, 155(1), 142-146.
• Toma, W., Kyte, S. L., Bagdas, D., Alkhlaif, Y., Alsharari, S. D., Lichtman, A. H., ... & Damaj, M. I. (2017). Effects of paclitaxel on the development of neuropathy and affective behaviors in the mouse. Neuropharmacology, 117, 305-315.